FILE:ALXN/ALXN-8K-20060531164737.txt.gz
EVENTS:	Other Events
TEXT:
ITEM: Other Events
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( General Instruction A.2. below):
see
 
 
 
 
 
Item 8.01 Other Events.
Further results of Alexion's recently completed Phase III trial of eculizumab in patients suffering from paroxysmal nocturnal hemoglobinuria ("PNH") will be presented on June 17 at the 11th Congress of the European Hematolgy Association (the "EHA") in Amsterdam, The Netherlands. Earlier this year Alexion reported that all pre-specified primary and secondary endpoints in this trial had been achieved with statistical significance. The EHA has advised Alexion that the associated Abstract will be available on its website beginning May 31, 2006. The Abstract is titled "Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in a Phase III Trial in Patients with Paroxysmal Nocturnal Hemoglobinuria"
EHA has advised Alexion that the Abstract may be viewed by going to ; then clicking on the link to the "11th Congress" (left side of page); then clicking on the link to "Accepted Abstracts" (left side of page); then clicking on the link to "Presidential Symposium: 6 best abstracts" (top of page); then clicking on the link to the Abstract (bottom of the page). EHA has advised Alexion that after completion of the 11th Congress, all abstracts will be available on its website by clicking on the link to "Previous Congresses".
www.ehaweb.org
www.ehaweb.org
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ALEXION PHARMACEUTICALS, INC.
 
Date: May 31, 2006
By:
/s/ Thomas I. H. Dubin                      
        Name: Thomas I. H. Dubin
        Title: Senior Vice President and General Counsel


